|
|
|
|
|
|
Sponsors and Collaborators: |
New York University School of Medicine Forest Laboratories Fisher Center for Alzheimer's Research Foundation |
Information provided by: | New York University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00120874 |
The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
Condition | Intervention | Phase |
Alzheimer's Disease |
Behavioral: Caregiver Training Home visits: exercising, doing activities Drug: memantine |
Phase IV |
Genetics Home Reference related topics: | Alzheimer disease |
MedlinePlus related topics: | Alzheimer's Caregivers Alzheimer's Disease Caregivers Dementia |
Drug Information available for: | Memantine Memantine hydrochloride |
Study Type: | Interventional |
Study Design: | Other, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial |
Estimated Enrollment: | 20 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | December 2008 |
Presently some 4.5 million people are afflicted with Alzheimer's disease in the United States. At present pharmacologic treatment, although beneficial, is not curative. Certain nonpharmacologic treatments have assisted caregivers of AD patients by reducing their stress and burden, and others have aided patients, by improving their mood and physical functioning. Comprehensive, individualized approaches to improving Alzheimer's patients' symptomatology and caregiver stress and burden have not been systematically investigated in Alzheimer's patient care. This study seeks to train and counsel caregivers as well as develop an individualized, comprehensive management program that will seek to enhance the functioning of each patient participant.
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Sunnie Kenowsky, D.V.M. | 212-263-7164 | sunnie.kenowsky@med.nyu.edu |
Contact: Thet Oo, M.D. | 212-263-8088 | thet.oo@med.nyu.edu |
United States, New York | |||||
Fisher Alzheimer's Program, New York University School of Medicine | Recruiting | ||||
New York, New York, United States, 10016 | |||||
Contact: Sunnie Kenowsky, D.V.M. 212-263-7164 sunnie.kenowsky@med.nyu.edu | |||||
Contact: Thet Oo, M.D. 212-263-8088 thet.oo@med.nyu.edu |
New York University School of Medicine |
Forest Laboratories |
Fisher Center for Alzheimer's Research Foundation |
Principal Investigator: | Barry Reisberg, M.D. | New York University School of Medicine |
Study Director: | Sunnie Kenowsky, D.V.M. | New York University School of Medicine |
Study ID Numbers: | H12444-01 A |
First Received: | July 12, 2005 |
Last Updated: | July 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00120874 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|
|